Kazia Therapeutics Limited Is An Australian Biotechnology Company Based In Sydneyspecializing In Oncologyfounded In 1994 And Rebranded In 2017Kazia Focuses On Developing Innovative Cancer Therapiesthe Company Operates With A Lean Structure And Emphasizes Cost Efficient Clinical Trial Execution And Strategic Partnerships Kazia S Key Products Include Paxalisiba Drug In Phase 3 Trials Targeting Glioblastoma And Other Cns Cancersand Evt801A Selective Vegfr3 Inhibitor In Phase 1 Trials For Advanced Solid Tumorsthe Company Advances Its Drug Candidates Through Clinical Developmentcollaborating With Organizations Such As Genentech And Evotec Sekazia S Approach Aims To Maximize Resource Allocation While Addressing Unmet Needs In Cancer Treatment
